In January 2026, two bellwether gatherings—the J.P. Morgan Healthcare Conference in San Francisco and the Consumer Electronics Show (CES) in Las Vegas—offered a preview of where life sciences and healthcare might be heading next.
Both events focused on how technology is becoming embedded in care delivery and consumer experiences. The most durable advantage is likely to come from organizations that embed AI and data across core workflows, rather than treating them as standalone innovations.
4 conference takeaways that signal what’s next for the life science and health-care industries
Here are four notable themes from those two events that illustrate how technology could impact life sciences and healthcare organizations in 2026 and beyond.
1. AI moves from innovation to infrastructure
There wasn’t much evidence of an AI bubble at either conference. AI’s adoption is seen as an essential strategy and infrastructure component rather than just an innovative technology.
Some companies are embedding AI across their operations. In healthcare, AI adoption is generally being incorporated into clinical workflows and may be used to automate some administrative tasks. Our new Deloitte research found that 85% of healthcare leaders intend to increase their investment in agentic AI over the next two or three years.
In the life sciences, some medtech companies use AI to enhance business functions such as human resources, revenue cycle management, research and development (R&D) and supply chain management. Some biopharma companies use AI for everything from drug discovery and clinical trial design to internal operations.
During conference sessions, pharma executives discussed the need to shift AI spending from their digital-innovation budgets to their core R&D and clinical operations profit-and-loss (P&L) accounts.
2. Devices empower consumers with potentially powerful information
Of course, the “consumer” is always front and center at the Consumer Electronics Show. But this year, there appeared to be more focus on how technology is being used to gather an individual’s health data—from rings, watches, and wristbands to a thin skin patch that uses perspiration to track biomarkers.
The wearable market is expected to accelerate from $314 billion in 2025 to $358 billion this year. But the data those devices collect won’t improve health unless consumers receive actionable insights and act on them.
We’re just beginning to see how AI can turn raw health data from sensors and wearables into actionable information. The question is whether wearable developers can do this on their own or partner with organizations to transform data into personalized actions, such as nudges, to help consumers improve their health.
3. New tariffs, regulations, and pricing policies create complexity
The still-unfolding effects of the July 2025 H.R. 1 (also known as the One Big Beautiful Bill Act) are among the myriad changes pharmaceutical companies appear to be tracking more closely, according to our recent Deloitte Center for Health Solutions survey.
In addition, new Center for Medicare and Medicaid Innovation models and policies—including the Inflation Reduction Act, the 340B drug-pricing program, and Most-Favored-Nation drug pricing—could have implications for life sciences and healthcare organizations this year.
Pharma companies might need to consider a strategic approach that balances market access, profitability, and compliance. The importance of cross-functional teams—including tax, information technology, strategy, finance, and operations—working together as part of an agile and hyper-adaptable system is critical to success.
4. Health span may become an investment theme
Many of the devices on the CES floor were designed to do more than passively collect user data. There was a focus on using technology to help people improve mobility, mental health, and detect disease in the earliest stages.
Living a healthy life can be central to achieving one’s life goals, whether they’re social, physical, emotional, financial, educational, or business-related. The average life expectancy in the U.S. is 79 years, according to a January 2026 report from the Centers for Disease Control and Prevention.
However, Americans spend just 85% of those years in good health, on average. According to an analysis by Deloitte’s actuaries, all Americans could live in good health for up to 95% of their lives, extending the average lifespan to nearly 90 years. Moreover, people who live longer, healthier lives will likely spend less money on health care over their lifetimes than those who are in poor health and die younger.
One takeaway from the JPM and CES conferences is that the next leap for life sciences and healthcare likely won’t come from a single breakthrough, gadget, or algorithm. It will likely result from lessons from other industries, as well as from AI and other digital technologies disappearing into workflows and becoming embedded in how organizations function and how care is experienced.
Jay Bhatt is managing director of the Deloitte Center for Health Solutions and Health Institute.